Trial Profile
A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CTX-SPL9111 (a cabazitaxel (CTX)-dendrimer conjugate) in patients with advanced solid tumours
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Cholangiocarcinoma; Gastric cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Starpharma
- 20 Jan 2024 Results(n=15) evaluating preliminary efficacy and safety results, presented at the 2024 Gastrointestinal Cancers Symposium
- 26 Oct 2023 According to a Starpharma media release, recent results from this study will be presented at the Wilsons Drug and Device Conference tomorrow, 27 October 2023, at 10:00 AM AEST.
- 18 Oct 2023 According to a Starpharma media release, Status changed from active, no longer recruiting to completed.